TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.

ISSN
2296-5262
2296-5270
Date Issued
2014
Author(s)
Nogova, L.
Gardizi, Masyar
Scheffler, M.
Papachristou, I.
Woempner, C.
Heukamp, Lukas Carl
Fuhr, Uwe
Sos, Martin L.
Eberhardt, W.
Wiesweg, Marcel
Schmid, Kurt Werner
Schuler, M.
Thomas, Roman K.
Buettner, Reinhardt
Wolf, J.